ABVC - ABVC BIOPHARMA, INC.

0.8948
0.065   7.242%

Share volume: 572,317
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.83
0.06
0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 0%
Dept financing 39%
Liquidity 25%
Performance 69%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
20.59%
1 Month
41.49%
3 Months
61.52%
6 Months
66.54%
1 Year
-24.17%
2 Year
-86.59%
Key data
Stock price
$0.89
P/E Ratio 
0.00
DAY RANGE
$0.80 - $1.01
EPS 
-$1.22
52 WEEK RANGE
$0.40 - $1.73
52 WEEK CHANGE
-$21.51
MARKET CAP 
8.478 M
YIELD 
N/A
SHARES OUTSTANDING 
12.422 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.01
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,419,577
AVERAGE 30 VOLUME 
$535,265
Company detail
CEO: Howard Doong
Region: US
Website: abvcpharma.com
Employees: 30
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ABVC BioPharma, Inc. develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer. ABV-1504 has completed Phase II clinical trials for major depressive disorders. ABV1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.

Recent news

ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million

FREMONT, CA - April 3, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced tha...

Read more

ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential

Expecting $19 Million Cash Income FREMONT, CA - March 19, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncol...

Read more

ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs

Over $100 Million Invested in the U.S. FREMONT, CA - March 5, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and ...

Read more